Biotech companies at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
135 biotech companies are at ASH 2026 — 132 presentations on the program and 57 with a booth in the exhibit hall. Most represented: Qihan Biotechnology (6 on the program), Incyte (5 on the program), BeOne Medicines (3 on the program). 64 of them have their own page in this guide. As of Nov 10, 2026.
Topic
Top represented
Showing 1–6 of 135 organizations
| Organization | ASH 2026 Attendance |
|---|---|
QB Qihan Biotechnology Hangzhou, China | |
Biotechnology company developing cell and gene therapies in Hangzhou, China. | Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Incyte Wilmington, DE | |
Biopharmaceutical company discovering, developing and marketing its own medicines in oncology and in inflammation and autoimmunity. | Booth Exhibiting at Booth 228, 1113 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Talk Sun Dec 13 11:30am–12:30pm Oral Sun Dec 13 4:30pm–6:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, whose medicines include the BTK inhibitor zanubrutinib for CLL and other B-cell cancers. | Booth Exhibiting at Booth 421 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Poster Sun Dec 13 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Genmab Copenhagen, Denmark | |
Danish antibody company developing bispecific antibodies and antibody-drug conjugates, including epcoritamab for lymphoma. | Booth Exhibiting at Booth 3229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Talk Mon Dec 14 12:15pm–1:15pm Poster Mon Dec 14 6:00pm–8:00pm |
Tessera Therapeutics Somerville, MA | |
Biotechnology company developing genetic medicines using gene writing. | Poster Sat Dec 12 5:30pm–7:30pm Oral Mon Dec 14 10:30am–12:00pm |
Syndax Pharmaceuticals Waltham, MA | |
Commercial-stage biotech with a menin inhibitor for relapsed or refractory acute leukemia and a CSF-1 receptor antibody for chronic GVHD. | Booth Exhibiting at Booth 3539 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. Session Sun Dec 13 11:15am–12:15pm Poster Sun Dec 13 6:00pm–8:00pm Talk Mon Dec 14 8:00am–9:00am Session |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 754
- Lymphoma & CLL 656
- Myeloma & Amyloidosis 374
- Bispecifics, ADCs & Targeted Drugs 510
- Transplant, Cell & Gene Therapy 521
- Sickle Cell, Anemia & Red Cell Disorders 359
- Bleeding, Clotting & Platelets 318
- Stem Cells & Blood Biology 671
- AI, Genomics & Data 204
- Clinical Practice & Access to Care 986
Exhibit hall
Program
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction